Vivek Daniel Paul is Chief Scientific Officer at GangaGen at Bangalore, India. At GangaGen, Vivek leads the discovery and development of novel non-traditional antibacterials to treat infections caused by drug-resistant bacteria. His areas of expertise are molecular genetics and protein engineering. Vivek was instrumental in developing an engineered Bacteriophages, Lysins and Bacteriocins platform at GangaGen and has several international patents to his credit.
Vivek is also currently leading a CARB-X funded project to develop antibacterial proteins called Klebicins as narrow-spectrum agents targeting Klebsiellapneumoniae, including the carbapenem-resistant and ESBL-expressing K. pneumoniae.